

Press release 2012-19-06

## WntResearch: New CFO to be engaged

**WntResearch AB (WNT.ST) announces that a new CFO is to be employed in the company after mutual agreement with Bert Junno. Bert Junno has played an important role in leading WntResearch from a small spin-out from Lund University to a listed company. There are several highly qualified candidates in the field and it is expected that a new CFO will be announced shortly.**

**Nils Brünner, CEO comments:**

I'm impressed by the results that Bert Junno has achieved for the Company and I wish to thank him for his important work in leading WntResearch from its very beginning as a small spin-out from Lund University to a company that is listed on Aktietorget.

WntResearch is now moving into the Clinical Development Phase and the Company wishes to take on a CFO with an international network to access potential Investors and partners for the development of Foxy-5. We are currently in contact with highly qualified candidates for the position and I look forward to announce the new CFO in the near future.

**For further information please contact:**

Nils Brünner, CEO

E-mail: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)

Telephone: +45 2614 4708

**About WntResearch AB**

*WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is currently being tested in in-vivo models and is planned to enter phase 1 clinical trials in metastatic cancer in 2012.*